Literature DB >> 20215518

Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin.

Subapriya Rajamanickam1, Balaiya Velmurugan, Manjinder Kaur, Rana P Singh, Rajesh Agarwal.   

Abstract

Chemoprevention is a practical and translational approach to reduce the risk of various cancers including colorectal cancer (CRC), which is a major cause of cancer-related deaths in the United States. Accordingly, here we assessed chemopreventive efficacy and associated mechanisms of long-term silibinin feeding on spontaneous intestinal tumorigenesis in the APC(min/+) mice model. Six-week-old APC(min/+) mice were p.o. fed with vehicle control (0.5% carboxymethyl cellulose and 0.025% Tween 20 in distilled water) or 750 mg silibinin/kg body weight in vehicle for 5 d/wk for 13 weeks and then sacrificed. Silibinin feeding strongly prevented intestinal tumorigenesis in terms of polyp formation in proximal, middle, and distal portions of small intestine by 27% (P < 0.001), 34% (P < 0.001), and 49% (P < 0.001), respectively. In colon, we observed 55% (P < 0.01) reduction in number of polyps by silibinin treatment. In size distribution analysis, silibinin showed significant decrease in large-size polyps (>3 mm) by 66% (P < 0.01) and 88% (P < 0.001) in middle and distal portions of small intestine, respectively. More importantly, silibinin caused a complete suppression in >3 mm sized polyps and 92% reduction in >2 to 3 mm sized polyps in colon. Molecular analyses of polyps suggested that silibinin exerts its chemopreventive efficacy by inhibiting cell proliferation, inflammation, and angiogenesis; inducing apoptosis; decreasing beta-catenin levels and transcriptional activity; and modulating the expression profile of cytokines. These results show for the first time the efficacy and associated mechanisms of long-term p.o. silibinin feeding against spontaneous intestinal tumorigenesis in the APC(min/+) mice model, suggesting its chemopreventive potential against intestinal cancers including CRC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20215518      PMCID: PMC2840193          DOI: 10.1158/0008-5472.CAN-09-3249

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Biomarkers of WNT signaling.

Authors:  Michael J Pishvaian; Stephen W Byers
Journal:  Cancer Biomark       Date:  2007       Impact factor: 4.388

Review 2.  The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis.

Authors:  William Cruz-Munoz; Rama Khokha
Journal:  Crit Rev Clin Lab Sci       Date:  2008       Impact factor: 6.250

Review 3.  Silymarin and epithelial cancer chemoprevention: how close we are to bedside?

Authors:  Manjinder Kaur; Rajesh Agarwal
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-15       Impact factor: 4.219

4.  Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.

Authors:  S Erdamar; P Bagci; B Oz; A Dirican
Journal:  J BUON       Date:  2006 Apr-Jun       Impact factor: 2.533

Review 5.  beta-Catenin signaling in biological control and cancer.

Authors:  Nancy Gavert; Avri Ben-Ze'ev
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

6.  Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin.

Authors:  Rana P Singh; Alpna Tyagi; Girish Sharma; Sarumathi Mohan; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

7.  Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse.

Authors:  Guoxiang Shen; Tin Oo Khor; Rong Hu; Siwang Yu; Sujit Nair; Chi-Tang Ho; Bandaru S Reddy; Mou-Tuan Huang; Harold L Newmark; Ah-Ng Tony Kong
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

Review 8.  The genetics of hereditary colon cancer.

Authors:  Anil K Rustgi
Journal:  Genes Dev       Date:  2007-10-15       Impact factor: 11.361

9.  The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse.

Authors:  S L Preston; S J Leedham; D Oukrif; M Deheregoda; R A Goodlad; R Poulsom; M R Alison; N A Wright; M Novelli
Journal:  J Pathol       Date:  2008-02       Impact factor: 7.996

Review 10.  Advances in the use of milk thistle (Silybum marianum).

Authors:  Janice Post-White; Elena J Ladas; Kara M Kelly
Journal:  Integr Cancer Ther       Date:  2007-06       Impact factor: 3.279

View more
  35 in total

1.  Silibinin prevents ultraviolet B radiation-induced epidermal damages in JB6 cells and mouse skin in a p53-GADD45α-dependent manner.

Authors:  Srirupa Roy; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Carcinogenesis       Date:  2011-12-12       Impact factor: 4.944

2.  Phytochemicals and colorectal cancer prevention--myth or reality?

Authors:  Luigi Ricciardiello; Franco Bazzoli; Vincenzo Fogliano
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-09-06       Impact factor: 46.802

3.  Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.

Authors:  Wenyan Lu; Cuihong Lin; Taj D King; Honghong Chen; Robert C Reynolds; Yonghe Li
Journal:  Cell Signal       Date:  2012-07-20       Impact factor: 4.315

4.  Ethanol-induced mast cell-mediated inflammation leads to increased susceptibility of intestinal tumorigenesis in the APC Δ468 min mouse model of colon cancer.

Authors:  Andre L Wimberly; Christopher B Forsyth; Mohammad W Khan; Alan Pemberton; Khashayarsha Khazaie; Ali Keshavarzian
Journal:  Alcohol Clin Exp Res       Date:  2013-01       Impact factor: 3.455

Review 5.  Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Authors:  Harold Ting; Gagan Deep; Rajesh Agarwal
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

6.  Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries.

Authors:  Neera Tewari-Singh; Anil K Jain; Swetha Inturi; David A Ammar; Chapla Agarwal; Puneet Tyagi; Uday B Kompella; Robert W Enzenauer; J Mark Petrash; Rajesh Agarwal
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-24       Impact factor: 4.219

Review 7.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

8.  Promise and potential of silibinin in colorectal cancer management: what patterns can be seen?

Authors:  Komal Raina; Rajesh Agarwal
Journal:  Future Oncol       Date:  2013-06       Impact factor: 3.404

9.  Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries.

Authors:  Komal Raina; Chapla Agarwal; Ritambhara Wadhwa; Natalie J Serkova; Rajesh Agarwal
Journal:  Autophagy       Date:  2013-02-27       Impact factor: 16.016

10.  Silibinin inhibits ultraviolet B radiation-induced DNA-damage and apoptosis by enhancing interleukin-12 expression in JB6 cells and SKH-1 hairless mouse skin.

Authors:  Sreekanth Narayanapillai; Chapla Agarwal; Gagan Deep; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2013-01-28       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.